Ratings by BMO Capital (David Lebowitz)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 9/23/2026 | Ionis Pharmaceuticals | IONS | Maintain | Market Perform (N/A) |
|
Details | ||
| 9/16/2026 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Outperform (N/A) |
|
Details | ||
| 9/10/2026 | Ascendis Pharma | ASND | Maintain | Outperform (N/A) |
|
Details | ||
| 9/8/2026 | Ionis Pharmaceuticals | IONS | Maintain | Market Perform (N/A) |
|
Details | ||
| 9/4/2026 | Ionis Pharmaceuticals | IONS | Maintain | Market Perform (N/A) |
|
Details | ||
| 8/31/2026 | Alnylam Pharmaceuticals | ALNY | Maintain | Outperform (N/A) |
|
Details | ||
| 8/18/2026 | Aktis Oncology | AKTS | New Coverage | Outperform (N/A) |
24.72 (17.34) |
-29.85% | Details | |
| 8/18/2026 | Bicara Therapeutics Inc | BCAX | New Coverage | Outperform (N/A) |
24.94 (17.33) |
-30.51% | Details | |
| 8/18/2026 | Alnylam Pharmaceuticals | ALNY | New Coverage | Outperform (N/A) |
224.60 (227.02) |
1.08% | Details | |
| 8/18/2026 | Ascendis Pharma | ASND | New Coverage | Outperform (N/A) |
247.40 (227.00) |
-8.25% | Details | |
| 8/18/2026 | Perspective Therapeutics Inc | CATX | New Coverage | Outperform (N/A) |
3.22 (2.52) |
-21.74% | Details | |
| 8/18/2026 | Ionis Pharmaceuticals | IONS | New Coverage | Market Perform (N/A) |
58.63 (43.67) |
-25.52% | Details | |
| 8/18/2026 | Prime Medicine | PRME | New Coverage | Outperform (N/A) |
3.17 (3.61) |
13.88% | Details | |
| 8/18/2026 | BioMarin Pharmaceutical Inc. | BMRN | New Coverage | Outperform (N/A) |
66.64 (55.39) |
-16.88% | Details | |
| 8/18/2026 | Exelixis | EXEL | New Coverage | Market Perform (N/A) |
52.32 (59.82) |
14.33% | Details |
